慢性淋巴细胞性白血病，出现淋巴结肿大较早。
Lymph node enlargement occurs early in chronic lymphocytic leukemia.
一些慢性淋巴细胞性白血病CLL患者在确诊后较长时间内并不急需移植疗法。
Some CLL patients do not need treatment for long periods of time after diagnosis.
他们发现通过这种试验，试验*物ABT-737易于标记慢性淋巴细胞性白血病。
Using the test, they found that chronic lymphocytic leukemia (CLL) is an "easy mark" for the experimental drug ABT-737.
美国每年约有10,000人被诊断为慢性淋巴细胞性白血病，慢淋目前是不可治愈的。
Each year, about 10,000 people in the United States are diagnosed with CLL, which is currently incurable.
慢性淋巴细胞性白血病的细胞依赖生存分子Bcl - 2，该分子可以关闭了癌症细胞的凋亡信号。
CLL cells are strongly dependent on a survival molecule called Bcl-2, which switches off self-destruct signals in the cancer cells.
“慢性”白血病少有或几乎没有母细胞。与急性白血病相比，“慢性淋巴细胞性白血病”和“慢性髓细胞性白血病”通常进程相对缓慢。
"Chronic" leukemias have few or no blast cells. "chronic lymphocytic leukemia" and "chronic myelogenous leukemia" usually progress slowly compared to acute leukemias.
有些病人在常规体检的血液检查后才知道他们患有慢性淋巴细胞白血病或慢性粒细胞性白血病。
Some patients learn they have CLL or CML after a blood test as part of a regular checkup.
相对于急性白血病，慢性淋巴细胞白血病和慢性粒细胞性白血病通常进展缓慢。
Chronic lymphocytic leukemia and chronic myelogenous leukemia usually progress slowly compared to acute leukemias.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
应用推荐